Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 416 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 416 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $32.10, for a total value of $13,353.60. Following the transaction, the insider owned 50,437 shares of the company’s stock, valued at $1,619,027.70. The trade was a 0.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30.

Mineralys Therapeutics Trading Down 2.5%

MLYS stock traded down $0.81 on Tuesday, hitting $31.93. The company had a trading volume of 1,174,735 shares, compared to its average volume of 1,066,947. Mineralys Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $47.65. The stock’s 50-day simple moving average is $37.86 and its 200 day simple moving average is $31.54.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on MLYS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Stifel Nicolaus boosted their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. HC Wainwright lifted their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Finally, Wells Fargo & Company boosted their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Institutional Trading of Mineralys Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Simplify Asset Management Inc. purchased a new position in Mineralys Therapeutics in the 3rd quarter worth approximately $8,294,000. Geode Capital Management LLC raised its position in shares of Mineralys Therapeutics by 19.0% during the second quarter. Geode Capital Management LLC now owns 954,560 shares of the company’s stock valued at $12,917,000 after buying an additional 152,560 shares during the last quarter. Voya Investment Management LLC purchased a new position in shares of Mineralys Therapeutics in the first quarter worth $255,000. 22NW LP lifted its holdings in shares of Mineralys Therapeutics by 21.4% in the second quarter. 22NW LP now owns 560,042 shares of the company’s stock worth $7,577,000 after buying an additional 98,698 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Mineralys Therapeutics during the first quarter worth $359,000. Institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.